Document 0852
 DOCN  M9550852
 TI    The impact of human immunodeficiency virus on response to treatment and
       recurrence rate in patients treated for tuberculosis: two-year follow-up
       of a cohort in Lusaka, Zambia.
 DT    9505
 AU    Elliott AM; Halwiindi B; Hayes RJ; Luo N; Mwinga AG; Tembo G; Machiels
       L; Steenbergen G; Pobee JO; Nunn PP; et al; School of Medicine,
       University of Zambia, Lusaka.
 SO    J Trop Med Hyg. 1995 Feb;98(1):9-21. Unique Identifier : AIDSLINE
       MED/95165491
 AB    To examine the effect of HIV on response to treatment and recurrence
       rate in patients with tuberculosis (TB), we have followed 239 previously
       untreated, adult, TB patients in a prospective cohort study in Lusaka,
       Zambia. One hundred and seventy-four (73%) were HIV-1 antibody positive.
       Patients with sputum smear positive, miliary, or meningeal TB were
       prescribed 2 months daily streptomycin, thiacetazone, isoniazid,
       rifampicin, pyrazinamide followed by 6 months thiacetazone and
       isoniazid; others, 2 months streptomycin, thiacetazone and isoniazid
       followed by 10 months thiacetazone and isoniazid. Thirty-five per cent
       of HIV-positive (HIV+ve) and 9% of HIV-negative (HIV-ve) patients were
       known to have died before the scheduled end of treatment. Surviving
       HIV+ve patients showed weight gain and improvement in symptoms and
       laboratory and radiological findings similar to HIV-ve patients. The
       risk of cutaneous drug reaction was 17% (95% CI: 12-25%) in HIV+ve, and
       4% (1-13%) in HIV-ve patients. Severe rashes were attributed to
       thiacetazone. Recurrence of active TB was examined among 64 HIV+ve and
       37 HIV-ve patients who successfully completed treatment, with mean
       follow-up after the end of treatment of 13.5 and 16.8 months,
       respectively. The rate of recurrence was 22/100 person years (pyr) for
       HIV+ve patients and 6/100 pyr for HIV-ve patients, giving a recurrence
       rate ratio of 4.0 (95% CI 1.2-13.8, P = 0.03).
 DE    Adult  Antitubercular Agents/*THERAPEUTIC USE  AIDS-Related
       Opportunistic Infections/*DRUG THERAPY  Drug Therapy, Combination
       Female  Follow-Up Studies  Human  *HIV-1  Male  Prospective Studies
       Recurrence  Support, Non-U.S. Gov't  Survival Analysis  Treatment
       Outcome  Tuberculosis/*DRUG THERAPY  Urban Health  Zambia  JOURNAL
       ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).